Authors:
Williams, JI
Weitman, S
Gonzalez, CM
Jundt, CH
Marty, J
Stringer, SD
Holroyd, KJ
McLane, MP
Chen, QM
Zasloff, M
Von Hof, DD
Citation: Ji. Williams et al., Squalamine treatment of human tumors in nu/nu mice enhances platinum-basedchemotherapies, CLIN CANC R, 7(3), 2001, pp. 724-733
Authors:
Zentner, GM
Rathi, R
Shih, C
McRea, JC
Seo, MH
Oh, H
Rhee, BG
Mestecky, J
Moldoveanu, Z
Morgan, M
Weitman, S
Citation: Gm. Zentner et al., Biodegradable block copolymers for delivery of proteins and water-insoluble drugs, J CONTR REL, 72(1-3), 2001, pp. 203-215
Authors:
Liu, L
Vapiwala, N
Munoz, LK
Winick, NJ
Weitman, S
Strauss, LC
Frankel, LS
Rosenthal, DI
Citation: L. Liu et al., A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors, MED PED ONC, 37(4), 2001, pp. 390-392
Authors:
Weitman, S
Marty, J
Jolivet, J
Locas, C
Von Hoff, DD
Citation: S. Weitman et al., The new dioxolane, (-)-2 '-deoxy-3 '-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts, CLIN CANC R, 6(4), 2000, pp. 1574-1578
Authors:
Hammond, LA
Hilsenbeck, SG
Eckhardt, SG
Marty, J
Mangold, G
MacDonald, JR
Rowinsky, EK
Von Hoff, DD
Weitman, S
Citation: La. Hammond et al., Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model, EUR J CANC, 36(18), 2000, pp. 2430-2436
Authors:
Eckhardt, SG
Baker, SD
Britten, CD
Hidalgo, M
Siu, L
Hammond, LA
Villalona-Calero, MA
Felton, S
Drengler, R
Kuhn, JG
Clark, GM
Smith, SL
MacDonald, JR
Smith, C
Moczygemba, J
Weitman, S
Von Hoff, DD
Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies, J CL ONCOL, 18(24), 2000, pp. 4086-4097
Authors:
Mendel, DB
Laird, AD
Smolich, BD
Blake, RA
Liang, CX
Hannah, AL
Shaheen, RM
Ellis, LM
Weitman, S
Shawver, LK
Cherrington, JM
Citation: Db. Mendel et al., Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent, ANTI-CAN DR, 15(1), 2000, pp. 29-41
Authors:
Weitman, S
Langevin, AM
Berkow, RL
Thomas, PJ
Hurwitz, CA
Kraft, AS
Dubowy, RL
Smith, DL
Bernstein, M
Citation: S. Weitman et al., A phase I trial of bryostatin-1 in children with refractory solid tumors: A pediatric oncology group study, CLIN CANC R, 5(9), 1999, pp. 2344-2348
Authors:
Petit, T
Izbicka, E
Lawrence, RA
Bishop, WR
Weitman, S
Von Hoff, DD
Citation: T. Petit et al., Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units, ANN ONCOL, 10(4), 1999, pp. 449-453
Authors:
Britten, CD
Izbicka, E
Hilsenbeck, S
Lawrence, R
Davidson, K
Cerna, C
Gomez, L
Rowinsky, EK
Weitman, S
Von Hoff, DD
Citation: Cd. Britten et al., Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay, CANC CHEMOT, 44(2), 1999, pp. 105-110
Authors:
Weitman, S
Mangold, G
Marty, J
Dexter, D
Hilsenbeck, S
Rake, J
Juniewicz, P
Von Hoff, D
Citation: S. Weitman et al., Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft, CANC CHEMOT, 43(5), 1999, pp. 402-408
Authors:
Britten, CD
Hilsenbeck, SG
Eckhardt, SG
Marty, J
Mangold, G
MacDonald, JR
Rowinsky, EK
Von Hoff, DD
Weitman, S
Citation: Cd. Britten et al., Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model, CANCER RES, 59(5), 1999, pp. 1049-1053
Authors:
Wadkins, RM
Potter, PM
Vladu, B
Marty, J
Mangold, G
Weitman, S
Manikumar, G
Wani, MC
Wall, ME
Von Hoff, DD
Citation: Rm. Wadkins et al., Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts, CANCER RES, 59(14), 1999, pp. 3424-3428